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West Nile virus (WNV) has become a major
public health concern in North America since
1999, when the ﬁrst outbreak in the Western
Hemisphere occurred in New York City,
causing 62 cases of human encephalitis and
7 deaths [Centers for Disease Control and
Prevention (CDC) 1999]. The initial out-
break in New York City is thought to have
affected 2.6% of the population (Hubalek
2001). In 2000, WNV spread to three states,
with 21 human cases of WNV infection and
2 deaths. In 2001, 66 human cases and
9 deaths were reported in 10 states, before
WNV spread westward, affecting all but
6 states in 2002 and causing the largest
arboviral encephalitis epidemic in U.S. history
(Huhn et al. 2003). A total of 4,156 human
cases were documented, with 284 deaths
reported (CDC 2003), and numbers contin-
ued to grow in 2003, when 46 states reported
9,862 human cases with 264 deaths (CDC
2004a). In 2004, 2,539 human cases and
100 deaths were reported in 41 states (Hayes
et al. 2005). Since the first appearance of
WNV in the United States in 1999, the CDC
has reported 16,706 documented human cases
and 666 deaths (CDC 2004b; Hayes et al.
2005); however, large numbers of human
infections may not be detected because of sig-
nificant underreporting of milder cases of
West Nile fever (Hubalek 2001; Huhn et al.
2003). Given the infection rate observed for
previous years, Peleman (2004) estimated that
1.5 million people were infected with the
virus in 2003. 
As a result of this ongoing disease out-
break, management of mosquitoes that vector
WNV throughout the United States and
Canada has necessitated using insecticides in
areas where they traditionally have not been
used or have been used less frequently. This
practice has raised concerns by the public
about risks from insecticide use. In a survey by
Hinten (2000), 54% of 880 people surveyed
were either equally afraid of WNV and pesti-
cides or were more afraid of the insecticides.
Since 1999, numerous concerns have been
raised by the public regarding the safety of
using insecticides to control mosquitoes
(Cohen 2003; Fehr-Snyder 2004; Fitz 2003).
Some of those concerned have even suggested
that the health risks from the insecticides
exceed those of WNV (Cohen 2003; Ziem
2005). These concerns by the public are not
exclusive to the WNV issue, but reﬂect long-
standing perceptions of risk from pesticides
(Peterson and Higley 1993; Slovic 1987). 
Risk assessment is a formalized basis for the
objective evaluation of risk in which assump-
tions and uncertainties are clearly considered
and presented [National Research Council
(NRC) 1983, 1996]. Human-health and eco-
logic risk can be described in quantitative terms
as a function of effect (also termed “hazard” or
“toxicity”) and exposure (NRC 1983). Risk
assessment typically uses a tiered modeling
approach extending from deterministic models
(tier 1) based on conservative assumptions to
probabilistic models (tier 4) using refined
assumptions [Society for Environmental
Toxicology and Chemistry (SETAC) 1994]. In
risk assessment, conservative assumptions in
lower-tier assessments represent overestimates
of effect and exposure; therefore, the resulting
quantitative risk values typically are conserva-
tive and err on the side of safety.
Unfortunately, few, if any, science-based
considerations of the risks of insecticide use
versus the risks from vectorborne diseases have
been examined. An understanding of the
human-health risks for both vectorborne dis-
eases and associated vector controls would aid
greatly in decision making by all stakeholders.
Therefore, the objective of this study was to
use risk assessment methodologies to evaluate
human-health risks from WNV and from the
insecticides used to control adult mosquitoes.
Materials and Methods
Problem formulation. Although WNV has
important effects on horses and birds, our
assessment of health risks from WNV focused
only on humans. Currently, effect and expo-
sure factors for WNV are poorly understood
(Loeb et al. 2005), making quantitative mod-
eling of risk difﬁcult. Therefore, we evaluated
documented health effects from WNV infec-
tion and determined potential population
risks based on reported frequencies. Because
of the relatively recent emergence of WNV in
North America, information on prevalence of
various effects of the disease should be
regarded as tentative.
Our tier-1 quantitative assessment of
human-health risks associated with insecticides
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West Nile virus (WNV) has been a major public health concern in North America since 1999, when
the ﬁrst outbreak in the Western Hemisphere occurred in New York City. As a result of this ongoing
disease outbreak, management of mosquitoes that vector WNV throughout the United States and
Canada has necessitated using insecticides in areas where they traditionally have not been used or
have been used less frequently. This has resulted in concerns by the public about the risks from
insecticide use. The objective of this study was to use reasonable worst-case risk assessment method-
ologies to evaluate human-health risks for WNV and the insecticides most commonly used to control
adult mosquitoes. We evaluated documented health effects from WNV infection and determined
potential population risks based on reported frequencies. We determined potential acute (1-day) and
subchronic (90-day) multiroute residential exposures from each insecticide for several human sub-
groups during a WNV disease outbreak scenario. We then compared potential insecticide exposures
to toxicologic and regulatory effect levels. Risk quotients (RQs, the ratio of exposure to toxicologic
effect) were < 1.0 for all subgroups. Acute RQs ranged from 0.0004 to 0.4726, and subchronic RQs
ranged from 0.00014 to 0.2074. Results from our risk assessment and the current weight of scien-
tiﬁc evidence indicate that human-health risks from residential exposure to mosquito insecticides are
low and are not likely to exceed levels of concern. Further, our results indicate that, based on human-
health criteria, the risks from WNV exceed the risks from exposure to mosquito insecticides.
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subchronic residential exposures after truck-
mounted ultra-low-volume (ULV) spraying of
mosquito adulticides. The dissemination of
mosquito adulticides by ULV application gen-
erates fine aerosol droplets that remain aloft
and target flying mosquitoes [U.S. Environ-
mental Protection Agency (EPA) 2002b].
Acute exposures were defined as single-day
exposures immediately after a spray event.
Subchronic exposures were defined as expo-
sures per day over a 90-day seasonal multispray
event. A total of 10 spray events were assumed
to occur on days 1, 4, 14, 17, 27, 30, 40, 43,
53, and 56. This design represents a reasonable
worst-case mosquito insecticide seasonal appli-
cation scenario, including during a human epi-
demic of WNV [Karpati et al. 2004; New
York City Department of Health (NYCDOH)
2001]. Chronic exposures (> 6 months) to
mosquito adulticides are unlikely. Additionally,
extrapolation of subchronic exposures to
chronic exposure time frames would result in
lower risks than with subchronic risks (NYC-
DOH 2001). Therefore, chronic risks were not
assessed in this study. 
Exposures to several population subgroups
were estimated to account for potential age-
related differences in exposure. Groups
included adult males, adult females, infants
(0.5–1.5 years of age), and children (2–3, 5–6,
and 10–12 years of age). Adult males were
assumed to weigh 71.8 kg, which represents
the mean body weight for all males > 18 years
of age, and adult reproductive females were
assumed to weigh 60 kg, which represents the
mean body weight for females between 13 and
54 years of age (U.S. EPA 1996). Children 5–6
and 10–12 years of age were assumed to weigh
21.1 and 40.9 kg, respectively. Infants
(0.5–1.5 years of age) and toddlers (2–3 years
of age) were assumed to weigh 9.4 and
14.3 kg, respectively. All weights for children
were derived from mean body weight values
for male and female children within their
respective age groups (U.S. EPA 1996).
Hazard identification. We conducted
human-health risk assessments for six insecti-
cide active ingredients (permethrin, pyrethrins,
resmethrin, phenothrin, malathion, and naled)
and one synergist (piperonyl butoxide).
Malathion and naled are in the organophos-
phate class of insecticides, and permethrin,
pyrethrins, resmethrin, and phenothrin are in
the pyrethroid class. The synergist, piperonyl
butoxide, is present in many formulations with
pyrethroids. All compounds are currently regis-
tered by the U.S. EPA for adult mosquito
management in the United States. 
Toxicity end points. Toxicity and dose–
response information for each compound were
reviewed for acute and subchronic exposure
durations. Toxicity end points in this assess-
ment were chosen based on U.S. EPA regula-
tory end points.We used inhalation, dermal,
and ingestion toxicity end points for each
respective exposure route and duration.
Ingestion reference doses (RfDs) were used as
the toxicity end points (acceptable daily expo-
sures) and were compared with total estimated
exposures (total body burden). Acute and
subchronic ingestion RfDs were calculated by
dividing the most sensitive toxic effect [typically
the no observed adverse effect level (NOAEL)]
by a series of uncertainty factors (typically a fac-
tor of 100 to account for intraspecies and inter-
species uncertainty) (Table 1).
Environmental concentrations and fate of
insecticides. We used the AERMOD, version
1.0 tier 1 air dispersion model (U.S. EPA
1999) to predict the 7.6 m (25 ft) and 91.4 m
(300 ft) air concentrations (micrograms per
cubic meter) of each insecticide within 1- and
6-hr time ranges after ULV application by a
truck-mounted sprayer. Estimates of environ-
mental concentrations are presented only for
truck-mounted ULV applications because our
modeling suggested that delivery of ULV
applications by aircraft resulted in substan-
tially less aerial and surface deposition (and
therefore less human exposure and risk). This
was also observed by the NYCDOH (2001). 
We used the following conservative
assumptions: a) each chemical had a 24-hr
half-life in air except for naled, which was
given a 18-hr half-life; b) the insecticides were
applied at the maximum application rate as
stated on each label; c) all of the insecticides
were susceptible to the same weather condi-
tions using standardized weather data from
Albany, New York, in 1988; d) all spray events
occurred at 2100 hr; and e) each spray release
was at 1.5 m. The chemical properties, appli-
cation rates, and predicted environmental con-
centrations for each active ingredient are listed
in Table 2.
Receptors were established within the
model on a Cartesian grid at ﬁve intervals of
West Nile virus and mosquito insecticide risks
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Table 1. Toxicologic effects and regulatory end points for the active ingredients.
Acute Subchronic
Compound End point Study and toxicologic effects End point Study and toxicologic effects
Malathion NOAEL = 50 mg/kg/daya Based on reduction in maternal bw gain in  NOAEL = 2.4 mg/kg/daya  Based on inhibition of blood enzyme activity at
RfD = 0.5 mg/kg/day a study with pregnant rabbitsa RfD = 0.024 mg/kg/day 50 ppm malathion in the diet in a 24-month
UF = 100 UF = 100 study in ratsa 
Naled NOAEL = 1.0 mg/kg/dayb  Based on inhibition of blood and brain NOAEL = 1.0 mg/kg/dayb  Based on inhibition of blood and brain enzymes
RfD = 0.01 mg/kg/day enzymes in a 28-day study in ratsb  RfD = 0.01 mg/kg/day in a 28-day study in ratsb 
UF = 100 UF = 100
Permethrin NOAEL = 25 mg/kg/dayc  Acute neurotoxicity study in rats NOAEL = 25 mg/kg/dayc  Acute neurotoxicity study in rats
RfD = 0.25 mg/kg/day LOEL = 75 mg/kg based on observations  RfD = 0.25 mg/kg/day LOEL = 75 mg/kg based on observations of
UF = 100 of clinical signs such as aggression, UF = 100 clinical signs such as aggression,
abnormal/decreased movement, and abnormal/decreased movement, and
increased body temperaturec  increased body temperaturec 
Resmethrin NOEL = 10 mg/kg/dayd Based on liver weight increases in a  NOEL = 10 mg/kg/dayd  Based on liver weight increases in a 6-month
RfD = 0.1 mg/kg/day 6-month study in dogsd  RfD = 0.1 mg/kg/day study in dogsd 
UF = 100 UF = 100
Phenothrin NOEL = 70 mg/kg/daye 13-week study in rats NOEL = 70 mg/kg/daye 13-week study in rats
RfD = 0.7 mg/kg/day LOEL = 216 mg/kg-day based on increases in  RfD = 0.7 mg/kg/day LOEL = 216 mg/kg-day based on increases in
UF = 100 liver weights and decreases in cholesterol UF = 100 liver weights and decreases in cholesterol
in both male and female ratse in both male and female ratse
Pyrethrins NOAEL = 20 mg/kg/dayf Acute neurotoxicity study in rats NOAEL = 4.37 mg/kg/dayf Rat chronic toxicity study
RfD = 0.07 mg/kg/day LOAEL = 63 mg/kg/day based on tremors RfD = 0.044 mg/kg/day LOAEL = 42.9 mg/kg/day based on increased
UF = 300 in femalesf UF = 100 incidence of thyroid follicular cell hyperplasia
in males.f
Piperonyl NOAEL = 630 mg/kg/dayg Developmental toxicity study in rats NOAEL = 89 mg/kg/dayg Two generation reproduction study in rats
butoxide RfD = 6.3 mg/kg/day LOAEL = 1,065 mg/kg/day based on decreases RfD = 0.89 mg/kg/day LOAEL = 469 mg/kg/day based on decrease in
UF = 100 in maternal bw gaing UF = 100 bw gain of F1and F2pups at postnatal day 2g
Abbreviations: bw, body weight; LOAEL, lowest observed adverse effect level. LOEL, lowest observed effect level; NOEL, no observed effect level; UF, uncertainty factor used to determine
the RfD.
aU.S. EPA 2000c. bU.S. EPA 2002a. cU.S. EPA 2005c. dU.S. EPA 2000a. eU.S. EPA 2000b. fU.S. EPA 2005b. gU.S. EPA 2005a.25 m at 7.6 m and 91.4 m from the edge of
the spray emission area. The receptors were at a
height of 1.5 m. Each receptor estimated the 1-
and 6-hr average air concentrations for each
insecticide. An average was then taken of the
estimates from the six receptors at 7.6 m that
were not at the edges of the spray zone. The
following data were obtained using this net-
work of receptors: the 1-hr average concentra-
tion at 7.6 m, the 6-hr average at 7.6 m, and
the peak value at 91.4 m.
We used the screening Industrial Source
Complex Short-Term (ISCST3) model (U.S.
EPA 1995) to estimate particle deposition
(milligrams per square meter) at 7.6 m and
91.4 m from the spray area at a 1-hr average.
The following assumptions were made in
addition to those from AERMOD: a) all of
the insecticides were susceptible to the same
weather conditions using standardized weather
data from Salem, Massachusetts; b) the ULV
particle size applications had 3% of the emit-
ted particles greater than the allowable particle
size as stated on the label; and c) the particles
were assigned a density in accordance with the
speciﬁc gravity of each insecticide.
A Cartesian grid was used for ISCST3 that
was similar to that used in AERMOD.
Receptors were added at 15.24-m intervals
between 7.6 m and 91.4 m from the spray
source to obtain a more accurate estimate of
the average deposition within 91.4 m of the
source. The receptors were also at the same
height of 1.5 m. All of the same methods were
used to calculate the average deposition at
7.6 m and 91.4 m. The middle receptors were
included to calculate an average deposition
within 91.4 m. The following data were
obtained from this information: deposition at
7.6 m, deposition at 91.4 m, and the average
deposition within 91.4 m of the spray source. 
For estimating subchronic exposures, we
used the estimated deposition values within
91.4 m for each insecticide in an exponential
decay model to characterize their persistence
on surfaces such as soil within a spray program
that included 10 sprays on days 1, 4, 14, 17,
27, 30, 40, 43, 53, and 56. Insecticide con-
centrations for each spray event were followed
through day 90 using the following multiple
degradation model:
[1]
where D is the sum of the deposition over one
spray, P is the peak deposition after a spray
event, r1 is the rate of decay calculated by using
the aerobic soil half-life of each active ingredi-
ent, r2 is the rate of decay calculated by using
the soil photolysis half-life of each active ingre-
dient, t is the time in hours, and j is the spray
day. The average daily exposure was then deter-
mined by dividing the deposition sum by 90.
The same deposition and degradation
model was used to characterize deposition and
persistence on garden produce by using a
Kenaga nomogram to estimate the deposition
(milligrams per kilogram dry weight) of each
insecticide on respective plant parts. Because
the nomogram represents a linear relationship
between application rate and maximum
residues, it can be used to estimate the maxi-
mum residues on plant surfaces for a given
application rate (Fletcher et al. 1994). For this
analysis, maximum application rates were used
for each insecticide, and each estimated con-
centration was then applied to the model
above, using the surface photolysis half-life to
estimate the rate of degradation.
Acute exposure. We assumed that multi-
route exposures immediately after a single-spray
event were limited to 24 hr. Routes of insecti-
cide exposure included inhalation, dermal con-
tact with spray, hand-to-mouth ingestion by
infants and toddlers from spray deposition on
hands, and ingestion of garden produce. We
also assumed that residents did nothing to limit
their exposure to the spray. In its assessment of
acute and subchronic exposures from several
mosquito adulticides, the NYCDOH (2001)
concluded that exposures from potable water
and swimming were negligible. Using environ-
mental fate models, we also concluded that the
chemical properties of the insecticides result in
negligible concentrations in water. Therefore,
we did not include these exposures in our
assessment.
Acute inhalation exposure. Acute inhala-
tion exposures were estimated as
PE = (EEC × RR ×D × CF) ÷ bw, [2]
where PE is potential exposure [milligrams per
kilogram body weight (bw)], EEC is the 6-hr
average estimated environmental concentration
of an active ingredient in the air 1.5 m high at
7.6 m from the spray source (micrograms per
cubic meter), RR is the respiratory rate under
moderate activity (cubic meters per hour), D is
the duration of exposure (hours), CF is the
conversion factor to account for the conversion
of units from micrograms per cubic meter to
milligrams per cubic meter, and bw is body
weight (kilograms).
RRs were assumed to be 1.6 m3/hr for
adults and 1.2 m3/hr for children, including
infants. These rates are indicative of moderate
physical activity (U.S. EPA 1996). The dura-
tion of exposure was 6 hr. Therefore, the
assumption was that the person was outside and
7.6 m from the spray truck when it passed him
or her. Moreover, the person remained outside,
7.6 m from the emission, for the following
6 hr, respiring as if under moderate physical
activity during the entire time. Body weight for
the different age groups is discussed above.
Acute dermal exposure from spray deposi-
tion. Acute dermal exposures from deposition
of spray drift on skin were estimated as
PE = (TDE × AB) ÷ bw, [3]
where PE is potential exposure (milligrams per
kilogram bw), TDE is total dermal exposure
(milligrams), AB is dermal absorption rate,
and bw is body weight (kilograms). There is
no publicly available information on dermal
deposition immediately after truck-mounted
ULV sprays. Therefore, we used the U.S. EPA
Pesticide Handler Exposure Database (PHED;
U.S. EPA 1998) as a conservative surrogate.
The PHED contains pesticide-handler scenar-
ios derived from field studies and exposure
estimates based on physical factors such as
application rate, hectares treated per day, type
of clothing worn, methods of application, and
Peterson et al.
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Table 2. Application rates, chemical properties, and predicted environmental concentrations of active ingredients.
Active ingredient
Property Piperonyl butoxide Phenothrin Permethrin Resmethrin Malathion Naled Pyrethrins
Application rate (kg ai/ha) 0.0392 0.004 0.0078 0.0078 0.0639 0.0224 0.009
Density (g/mL) 0.898a 0.898a 0.8657b 0.87c 1.23d 1.67e 0.81f
Surface photolysis half-life (days) NAg 6c 23h 0.14i 6.5i 2.4i 0.5j
Soil aerobic half-life (days) 14i 7i 37k 30h 1h 1h 1j
Acute air concentration (µg/m3)l 7.39 0.81 1.55 1.61 9.76 1.68 1.7
1-Day acute produce concentration (mg/kg dry wt) 0.525 0.054 0.105 0.105 0.855 0.3 0.12
90-Day mean surface concentration (mg/m2)m 15.42 0.43 4.14 0.22 2.18 0.65 0.54
90-Day mean produce concentration (mg/kg dry wt) 2.88 0.055 0.096 0.012 0.73 0.13 0.21
Abbreviations: ai/ha, active ingredient per hectare; NA, not available; wt, weight. 
aClarke Mosquito Control Products (1999b). bClarke Mosquito Control Products (1999a). cBayer Environmental Science (2004). dGrifﬁn (2001). eAMVAC (2003). fMcLaughlin Gormley King Co.
(2004). gSurface and produce concentrations determined from soil aerobic half-life only. hU.S. Department of Agriculture (USDA 2005). iNYCDOH (2001). jFood and Agricultural Organization
(2000). kU.S. EPA (2005c). l6-Hr mean concentration at 7.6 m from spray source. m90-Day mean surface concentration within 91.4 m of the spray source.formulation type. We used the PHED sce-
nario in which a ﬂagger (person marking the
location for pesticide application while the
application is occurring) was exposed to a liq-
uid application. We assumed that the person
was not wearing clothing and that the expo-
sure was 10 times greater than the ﬂagger sce-
nario. We believe this scenario conservatively
estimated residential dermal exposure for two
reasons: a) we added a 10-fold increase in
exposure, and b) the U.S. EPA has not consid-
ered acute dermal contact from ULV applica-
tions for pyrethrins, piperonyl butoxide, and
permethrin because it was believed to be negli-
gible (U.S. EPA 2005a, 2005b, 2005c). The
values for percent dermal absorption were
0.22% for pyrethrins (U.S. EPA 2005b), 2%
for piperonyl butoxide (U.S. EPA 2005a),
10% for malathion and resmethrin (U.S. EPA
2000a, 2000c), 15% for permethrin (U.S.
EPA 2005c), 70% for phenothrin (U.S. EPA
2000b), and 100% for naled (U.S. EPA
2002a).
Acute hand-to-mouth exposure from
spray deposition on hands. Acute hand-to-
mouth exposures were estimated for only two
subgroups (toddlers and infants), because
young children are more likely than adults to
be exposed to pesticides as a result of hand-to-
mouth contact (Cohen Hubal et al. 2000).
Exposures were calculated as
PE = [(THD ÷ HSA) × AHS × SEF] ÷ bw, [4]
where PE is potential exposure (milligrams per
kilogram bw), THD is total hand dermal expo-
sure (milligrams), HSA is adult hand surface
area (square meters), AHS is adjusted hand sur-
face area for each subgroup (square meters),
SEF is saliva extraction factor, and bw is body
weight (kilograms). Total hand dermal expo-
sure was determined using the PHED database
and the assumptions discussed above. The
hand surface area of toddlers (2–3 years of age)
was assumed to be 0.035 m2, which represents
the 50th percentile total surface area values for
males and females in the 2–3 and 3–4 year age
groups, multiplied by the mean percentage of
the total body represented by hands for males
and females of that age (U.S. EPA 1996). The
hand surface area for infants was assumed to be
0.007 m2 and was also calculated as a percent
of total body surface area for infants (U.S. EPA
1996). We calculated the total body surface
area of infants using the formula by Current
(1998). We assumed that, on the day of appli-
cation, 50% of the insecticide deposited on the
hand was available through saliva extraction
(U.S. EPA 2005a, 2005c).
Acute ingestion of garden produce. We
assumed that the insecticide settled onto a
tomato garden and that the resident picked,
processed, and ate tomatoes the next day. The
estimated maximum insecticide residue
deposited on tomatoes is discussed above. We
assumed that the resident did not wash the
tomatoes after picking. The residue concentra-
tion also did not change with processing of the
tomatoes. The amount of insecticide ingested
was estimated as the product of the residue con-
centration and the quantity of food consumed.
Tomato consumption patterns were deter-
mined using the Dietary Exposure Evaluation
Model [(DEEM)-Food Commodity Intake
Database (FCID) version 2.04; Exponent,
Washington, DC]. The model determines
dietary consumption for the U.S. population
and several subgroups by using individual
food consumption records collected by the
U.S. Department of Agriculture (USDA)
Continuing Surveys for Food Intake by
Individuals for 1994–1998. Translation fac-
tors used to convert foods-as-eaten to com-
modities are based on a U.S. EPA/USDA
FCID recipe set. For this assessment, we
determined the acute food consumption pat-
terns by subgroup using the 95th percentile
1-day consumption values for tomatoes,
tomato baby food, tomato paste, tomato paste
baby food, tomato puree, tomato puree baby
food, dried tomato, dried tomato baby food,
and tomato juice. Therefore, the respective
individuals in these subgroups ate all of these
tomato food products within 1 day of applica-
tion at the 95th percentile of U.S. national
consumption.
Subchronic exposure. We assumed multi-
route exposures per day over 90 days after
multispray events. Routes of insecticide expo-
sure included inhalation, dermal contact with
spray, ingestion of garden produce, hand-to-
mouth ingestion by infants and toddlers from
spray deposition on hands, hand-to-mouth
ingestion by infants and toddlers from deposi-
tion on surfaces, dermal contact with soil and
other surfaces, and soil ingestion.
Subchronic inhalation, dermal, and
hand-to-mouth exposures. Exposures for each
exposure type were estimated as
PE = (PEacute, type × SE) ÷ D, [5]
where PE is the potential exposure (milligrams
per kilogram bw per day), PEacute, type is the
acute exposure type (e.g., acute inhalation)
from each spray event (milligrams per kilo-
gram bw), SE is the number of spray events,
and D is the duration of exposure (days). We
assumed that the insecticides were sprayed on
days 1, 4, 14, 17, 27, 30, 40, 43, 53, and 56
(10 spray events per season) in any given area.
The exposure duration was 90 days.
Subchronic hand-to-mouth exposure
from deposition on surfaces. Subchronic
hand-to-mouth exposures were estimated for
only two subgroups (toddlers and infants)
based on the rationale discussed above.
Exposures were calculated as
PE = (EEC × SEF × SA × DR × FA × D) 
÷ bw, [6]
where PE is potential exposure (milligrams per
kilogram bw per day), EEC is the 90-day aver-
age environmental concentration of the active
ingredient deposited on soil or turf within
91.4 m from the spray source (milligrams per
square meter), SEF is saliva extraction factor,
SA is surface area for three fingers (square
meters), DR is dislodgeable residue, FA is fre-
quency of activity (events per hour), D is
exposure duration (hours), and bw is body
weight (kilograms). Assumptions for estimat-
ing subchronic environmental concentrations
are discussed above. The saliva extraction fac-
tor was assumed to be 50% (U.S. EPA 2005a,
2005c), and the palmar surface area for three
ﬁngers was assumed to be 20 cm2 (U.S. EPA
2005c). Dislodgeable insecticide residue from
soil or turf grass was assumed to be 20% (U.S.
EPA 1997). The frequency of hand-to-mouth
activity in children was assumed to be
20.5 events/hr and is based on the maximum
frequency observed (Freeman et al. 2005).
The duration of exposure was assumed to be
4 hr/day. Therefore, the toddler or infant was
assumed to be engaging in hand-to-mouth
activities outside each day for 4 hr over 90 days.
Subchronic ingestion of garden produce.
Our assumptions for subchronic ingestion of
garden produce were the same as for acute
ingestion of produce, with the following differ-
ences: a) the insecticide was deposited onto
both tomatoes and head- and leaf-lettuce, b) all
tomato and lettuce consumption by the resi-
dents over the 90 days was from the garden,
and c) tomato and lettuce consumption pat-
terns were determined using chronic food con-
sumption patterns (3-day average).
Subchronic dermal contact with soil and
other surfaces. Exposures from contact with
soil, turf, and other outdoor surfaces were
calculated as
PE = (EEC × SA ×SS ×AB × DR × CF) 
÷ bw, [7]
where PE is potential exposure (milligrams per
kilogram bw per day), EEC is the 90-day aver-
age environmental concentration of the active
ingredient deposited on soil or turf within
91.4 m from the spray source (milligrams per
square meter), SA is body surface area in con-
tact with surface (square centimeters), SS is
weight of soil adhered to skin (milligrams per
square centimeter), AB is dermal absorption
rate, DR is dislodgeable residue, CF is the con-
version factor to account for square meters to
square centimeters, and bw is body weight
(kilograms). The body surface area in contact
with the surface was assumed to be the sum of
surface areas for face (head ÷ 2), hands, arms,
legs, and feet (U.S. EPA 1996). Therefore, we
West Nile virus and mosquito insecticide risks
Environmental Health Perspectives • VOLUME 114 | NUMBER 3 | March 2006 369assumed residents were minimally clothed
while outside. Contact with surfaces was asso-
ciated with certain human activities. The activ-
ities were assumed to be gardening for adults
(0.55 mg soil/cm2 skin) and soccer for chil-
dren, including infants (0.164 mg soil/cm2
skin) (U.S. EPA 1996). We assumed that these
activities occurred each day over the 90 days.
The assumptions for dermal absorption rate
and dislodgeable residues are discussed above.
Subchronic soil ingestion. Exposures from
incidental ingestion of soil were calculated as
PE = [(EEC ÷ SW) × SI] ÷ bw, [8]
where PE is potential exposure (milligrams per
kilogram bw per day), EEC is the 90-day aver-
age environmental concentration of the active
ingredient deposited on soil or turf within
91.4 m from the spray source (milligrams per
square meter), SW is soil weight (milligrams
per cubic meter), SI is soil ingestion (mil-
ligrams per day), and bw is body weight (kilo-
grams). Because the insecticide would only be
surface-deposited on soil, we assumed that the
concentration (milligrams per square meter)
would be the same for a cubic meter of soil.
Soil weight was assumed to be 3.86 kg/m3
based on reported densities for Scotts lawn soil
(The Scotts Company, Marysville, OH). Soil
ingestion rates were assumed to be 100 mg/day
for children and 50 mg/day for adults (U.S.
EPA 1996). We assumed that all soil ingestion
each day was from soil containing residues of
the active ingredients.
Risk characterization. Human-health risks
in this study were assessed by integrating toxic-
ity and exposure. We assessed risks using the
risk quotient (RQ) method. For each popula-
tion subgroup, an RQ was calculated by divid-
ing the PE by the appropriate toxicity end
point (e.g., the RfD). Therefore, the RQ is the
ratio of exposure to effect. RQs < 1 are typi-
cally below regulatory levels of concern.
Exposures by similar route of exposure and
duration (e.g., subchronic dermal contact with
spray and surfaces) were compared with the
appropriate RfD (e.g., subchronic dermal
RfD). Multiroute exposures (dermal + inges-
tion + inhalation) were compared with the
ingestion RfD. The ingestion RfD provided a
conservative toxicity end point because it typi-
cally was based on the most sensitive NOAEL.
Therefore, it represented the largest dose in
which no adverse effects on human health
would occur during the relevant exposure
duration.
Results
West Nile virus risks. According to a sero-
epidemiologic survey conducted by Mostashari
et al. (2001), for every diagnosed case of West
Nile (WN) meningoencephalitis, there were
approximately 30 additional people with WN
fever, and approximately 2.6% of the popula-
tion in outbreak areas in New York were
infected during the epidemic of 1999. Loeb
et al. (2005) reported a 3.1% outbreak infec-
tion rate in Oakville, Ontario, Canada, in
2002. Unfortunately, the seroprevalence of
WNV antibodies across larger time and geo-
graphic scales has not been determined.
Overall, 20% of infected persons develop mild
febrile illness (Mostashari et al. 2001), and
0.67% develop neurologic disease (Fratkin
et al. 2004). A total of 0.43% develop
encephalitis, and 0.24% develop meningitis
(Asnis et al. 2001; Brilla et al. 2004; Emig and
Apple 2003; Klee et al. 2004; Sejvar et al.
2003a; Weiss et al. 2001).
Case-fatality rates in the United States
ranged from 4 to 18% among hospitalized
patients (Brilla et al. 2004; Emig and Apple
2003; Nash et al. 2001b; Pepperell et al. 2003;
Sejvar et al 2003a; Weiss et al. 2001) and from
2.7 to 14% among cases reported to the CDC
(CDC 2004b).
No difference in distribution of WNV
infection among age groups and between sexes
is apparent (Nash et al. 2001a, 2001b; Tyler
2001), but for unknown reasons, males seem
to be at higher risk for WN neuroinvasive ill-
ness (O’Leary et al. 2004; Petersen and Marﬁn
2002). Children infected with WNV usually
show no symptoms or have only a mild fever
(Hayes and O’Leary 2004). The incidence of
encephalitis and death increases with age (Nash
et al. 2001a, 2001b; O’Leary et al. 2004; Tsai
et al. 1998; Weinberger et al. 2001). Weiss
et al. (2001) reported that persons ≥ 50 years
of age were more likely to present meningo-
encephalitis and had increased mortality rates;
other reports show that the incidence of neuro-
logic symptoms and death may increase 10- to
20-fold among persons ≥ 50 years of age (Nash
et al. 2001a; Sampathkumar 2003; Tyler
2001). The risk increases 43 times for persons
≥ 80 years of age (Sampathkumar 2003).
Few data exist regarding long-term mor-
bidity after WNV infection. Substantial mor-
bidity may follow hospitalization for WNV
infection (Petersen et al. 2003) and is observed
in patients with WN fever (Watson et al.
2004). Encephalitis cases seem to have more
variable outcomes than meningitis cases, which
tend to recover well (Granwehr et al. 2004). A
poor prognosis and very limited recovery have
been observed in acute ﬂaccid paralysis cases
(Saad et al. 2005; Sejvar et al. 2003a, 2003b).
Although patients with WN fever tend to
recover well, median recovery time was 60 days
for patients in Illinois in 2002 (Watson et al.
2004). The disease also has a signiﬁcant effect
on the lifestyle of patients with WN fever. Of
98 respondents with WN fever, 57 (58%)
missed work/school, 82 (84%) had household
activities limited, 47 (49%) had difficulty
walking, and 89 (91%) had outside-of-home
activities limited (Watson et al. 2004). 
In a long-term follow-up study on 42 WN
encephalitis survivors 1 year after illness onset,
only 37% presented full physical, functional,
and cognitive recoveries, and there was a sub-
stantially higher prevalence of impairment
compared with baseline (Nash et al. 2001a).
Similarly, only 2 of 8 patients in a study in
New York presented full recovery after 1 year;
3 patients had neurologic sequelae, and
1 patient had minimal impairment after
18 months (Asnis et al. 2001). 
Acute risks from insecticides. Table 3 shows
the calculated RQs for each active ingredient in
terms of total acute PE. Exposures and risks
also were determined for each exposure route.
Potential acute inhalation exposures of the six
human subgroups to the adulticides ranged
from 0.00011 to 0.0075 mg/kg bw, and the
environmental concentrations were lower than
Peterson et al.
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Table 3. Acute RQs for the active ingredients for each subgroup.a
Piperonyl
Subgroup Malathion Naled Permethrin Resmethrin Phenothrin Pyrethrins butoxide
Adult males 0.0076 0.1496 0.0020 0.0052 0.0004 0.0081 0.0004
Adult females 0.0079 0.1576 0.0021 0.0055 0.0004 0.0085 0.0004
Children (10–12 years) 0.0105 0.2123 0.0029 0.0072 0.0006 0.0113 0.0006
Children (5–6 years) 0.0177 0.3631 0.0049 0.0123 0.0010 0.0190 0.0009
Toddlers (2–3 years) 0.0225 0.4726 0.0063 0.0159 0.0013 0.0245 0.0012
Infants (0.5–1.5 years) 0.0188 0.4495 0.0058 0.0147 0.0012 0.0218 0.0010
aRQ = total acute PE ÷ RfD.
Table 4. Subchronic RQs for the adulticides for each subgroup.a
Piperonyl
Subgroup Malathion Naled Permethrin Resmethrin Phenothrin Pyrethrins butoxide
Adult males 0.0360 0.0259 0.0007 0.0004 0.0001 0.0056 0.0032
Adult females 0.0363 0.0269 0.0007 0.0004 0.0001 0.0056 0.0032
Children (10–12 years) 0.0470 0.0290 0.0008 0.0005 0.0001 0.0074 0.0043
Children (5–6 years) 0.0676 0.0447 0.0012 0.0009 0.0002 0.0104 0.0059
Toddlers (2–3 years) 0.1815 0.1294 0.0204 0.0037 0.0009 0.0270 0.0262
Infants (0.5–1.5 years) 0.2074 0.1661 0.0301 0.0054 0.0013 0.0292 0.0325
aRQ = total subchronic PE ÷ RfD.the inhalation reference concentrations for all
active ingredients evaluated. Potential acute
dermal exposures to the adulticides ranged
from 0.0000001 to 0.0011 mg/kg bw, with
RQs ranging from 0.0000005 to 0.0113. For
acute exposure due to ingestion (hand-to-
mouth exposure from spray deposition on
hands and ingestion of produce), total PEs
ranged from 0.0001 to 0.0061 mg/kg bw, with
RQs ranging from 0.00014 to 0.2142. Total
acute RQs ranged from 0.0004 to 0.4726.
Subchronic risks from insecticides. Table 4
shows the calculated RQs for each active
ingredient in terms of total subchronic PE.
Potential subchronic inhalation exposures of
the six subgroups to the adulticides ranged
from 0.000012 to 0.00083 mg/kg bw. For
subchronic dermal exposures to the adulticides
(dermal and contact with soil), total PEs
ranged from 0.00000006 to 0.00015 mg/kg,
with RQs ranging from 0.0000001 to 0.0015.
Potential subchronic exposures due to inges-
tion (ingestion of produce and soil, hand-to-
mouth activity after contact with surfaces,
and hand-to-mouth activity after contact
with spray drift) ranged from 0.00001 to
0.0283 mg/kg bw, with RQs ranging from
0.00007 to 0.1709. Total subchronic RQs
ranged from 0.00014 to 0.2074.
None of the subgroups had RQs ≥ 1.0
(i.e., PEs did not equal or exceed the RfDs) for
any of the active ingredients evaluated. The
lowest acute RQs were to phenothrin and
piperonyl butoxide for adults and the highest
acute RQ was to naled for toddlers (Table 3).
The lowest and highest subchronic RQs were
to phenothrin for adults and malathion for
infants, respectively (Table 4).
Discussion
Conservatism. Based on the exposure and toxi-
city assumptions above, we believe our
assumptions were sufﬁciently conservative and
most likely overestimated risk. For example,
assuming an acute RR of 0.8 m3/hr for 2 hr
and no dermal or ingestion exposures [which
were the U.S. EPA assumptions for mosquito
control uses of permethrin (U.S. EPA 2005c)],
there would be a 90% reduction in exposure
for toddlers compared with our value. Indeed,
draft tier 1 risk assessments recently conducted
for malathion, piperonyl butoxide, pyrethrins,
and permethrin by the U.S. EPA also suggest
that our results are sufficiently conservative
(U.S. EPA 2000c, 2005a, 2005b, 2005c).
Because of the conservative exposure assump-
tions used, we believe higher-tiered risk assess-
ments using more realistic exposures would
result in risk values significantly lower than
those presented here.
The conservatism of our risk assessments
for insecticides used in adult mosquito con-
trol is supported by residential biomonitoring
and epidemiologic studies. Currier et al.
(2005) assessed human exposure to ULV-
applied naled, permethrin, and phenothrin in
Mississippi, North Carolina, and Virginia as
a result of emergency large-scale mosquito
abatement. Using biomonitoring of urine,
they did not observe an increase in insecti-
cide metabolite concentrations among
exposed residents. Karpati et al. (2004) and
O’Sullivan et al. (2005) did not observe
increases in hospital emergency department
visits for asthma after wide-scale spraying of
residential neighborhoods. 
Uncertainties. Despite the conservatism of
our risk assessment, uncertainties were
revealed. Many of the uncertainties associated
with residential exposure estimates are dis-
cussed above. The principal uncertainty was
for environmental concentrations of the active
ingredients. Data for actual aerial concentra-
tions and surface deposition of active ingredi-
ents need to be generated to more accurately
characterize risks. Because of the nature of
ULV application methods, it is likely that con-
centrations of active ingredients are much
lower than those predicted using the AER-
MOD and ISCST3 tier 1 models. Toxicologic
uncertainties include mammalian toxicities to
combinations of piperonyl butoxide and adul-
ticides and to inert ingredients in the formu-
lated products. The addition of piperonyl
butoxide to the adulticides increases the mos-
quito toxicity of the pyrethroids approxi-
mately 10-fold, but mammalian toxicity is not
likely to be proportionally increased (Knowles
1991). Even if mammalian toxicity were
increased 10-fold to the pyrethroids, RQs
would still be well below levels of concern.
Human exposures to solvents and other inert
ingredients are likely to be low, resulting in
low risks (NYCDOH 2001). Future research
should be directed toward reducing toxicity
and exposure uncertainties associated with
mosquito adulticides. In addition, future
assessments should address ecologic risks.
Comparing risks. Although it is difﬁcult to
compare the risks directly, several conclusions
can be drawn by considering both human
risks from exposure to WNV and insecticides
used to control adult mosquitoes. In a situa-
tion where application of mosquito adulticides
occurs because of known human cases of
WNV, an adult human female may have at
least a 3% probability of being infected by
WNV. An adult female in that same area con-
servatively may have a 100% probability of
being exposed to a particular mosquito adulti-
cide. Her probability of exposure to the insec-
ticide may be greater than WNV infection,
but the consequences (i.e., the risks) of the
exposures would be very different. Once
infected with WNV, an adult human female
has approximately a 20% probability of
expressing clinical signs of illness (WN fever)
and, depending on age, a 0.67% probability of
expressing neurologic disease. Depending on
the insecticide, her acute exposure would be
0.0415–15.76% of the RfD (0.0004–0.1576%
of the NOAEL). Consequently, her acute risks
from the insecticide would be lower than her
acute risks from WNV. Subchronic insecticide
risks would also be negligible (Table 4),
whereas subchronic and chronic WNV risks
(disease sequelae) would be greater. Therefore,
once exposed to the insecticide (based on the
tier 1 exposure assumptions from this study),
the risk of any adverse health effects to the
adult female would be negligible.
Results from our risk assessment and the
current weight of scientiﬁc evidence (Currier
et al. 2005; Karpati et al. 2004; NYCDOH
2001; O’Sullivan et al. 2005; U.S. EPA 2000c,
2005a, 2005b, 2005c) indicate that human-
health risks from residential exposure to mos-
quito adulticides are very low and are not likely
to exceed levels of concern. Further, by virtu-
ally any current human-health measure, the
risks from infection by WNV exceed the risks
from exposure to mosquito insecticides.
Therefore, perceptions that human-health risks
from the insecticides used to control adult
mosquitoes are greater than the risks from
WNV currently cannot be supported by cur-
rent scientific evidence. Our results, and the
results from other studies, should be used by
the U.S. EPA, public health ofﬁcials, and the
general public to make better-informed deci-
sions about risk–risk tradeoffs.
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